drug toxicity -that produced from a large single dose. The potential lethality of these acute ingestions can be influenced by the pharmacist at several points in the preingestion and postingestion phases.
The drug selection process is complex and one in which many pharmacists have significant input. Drug and patient related variables must be considered. The presence of an appropriate indication, lack of contraindications in the patient for whom the drug is prescribed and selection of appropriate dosage are important components of this process. A commonly overlooked criterion is the acute overdose potential of the prescribed agent. Acute ingestions of supertherapeutic doses occur frequently in several ways; by accident (mostly in young children), for drug abuse and for suicide. To reduce this potential toxicity, for example, if a sedative hypnotic is indicated and several would be acceptable in a given patient, the agent with the least acute overdose potential should be selected. Of sedative hypnotics, flurazepam is much safer in acute overdosage than are glutethimide, ethchlorvynol, barbiturates and others. According to the Albany College of Pharmacy's 20th Annual Prescription Survey, while flurazepam is currently the most commonly prescribed sedative hypnotic, it still accounts for only one fifth of total prescriptions written for hypnotics that are filled in community pharmacies. Clearly one of the reasons Dalmane® is prescribed frequently is its low acute overdose toxicity. Still, each month, many prescriptions are written, and filled, for Doriden® and Placidyl®, two of the most difficult sedative hypnotic intoxications to treat.
Since potential lethality depends on the amount in-gested, the amount dispensed becomes important. Tricyclic antidepressants (TCAs) are commonly taken for suicidal purposes. These drugs are potentially very toxic and have recently been reviewed in THIS JOURNAL by Bryan, et al. 1 An acute single dose of amitriptyline as low as approximately 500 mg has produced a fatality in an adult. 2 Other deaths in adults who have ingested under 1 gram of amitriptyline have also been reported. Consideration of potentially lethal doses of tricyclic antidepressants is particularly difficult since there is such a large amount of individual patient variation. If, however, one considers 1 gram to be a potentially lethal dose, this amount is contained in a one week supply for a patient maintained on 150 mg per day. In this same patient, a months supply, 4500 mg, is clearly within the lethal range for most adults and thus prescribing or dispensing large amounts of these, and other drugs, is clearly to be discouraged. In a recent letter to THIS JOURNAL discussing TCA intoxications, 3 Tong, et al., states, ". . . yet quantities several times the number considered to be lethal were frequently prescribed and dispensed. The overdose usually occurred during the first week after the prescription was filled."
The same problem occurs with OTC products. Acetaminophen in an acute dose of 200 mg/kg has the potential for producing irreversible hepatic necrosis in an adult. 4 (Children appear to be more resistant to this effect.) Thus for a 70 kg adult, an acute dose of 14 grams, or approximately 43 tablets of 325 mg of acetaminophen, is potentially life threatening; an amount far less than that contained in the commonly sold 100 tablet container.
Is the answer to this problem that by law no company could package a potentially lethal dose of an OTC drug in a single container? This may be helpful in reducing potential lethality in children. Whether the same effect would be seen in adults is less certain. A potentially suicidal adult could easily purchase more than one bottle. In addition, limiting the amount of adult medicine to a potential lethal dose for a child would limit the size of the container to hold unrealistically small amounts, perhaps 10-12 adult aspirin or acetaminophen tablets as the maximum per package. An alternate solution would be to require child resistant packaging for all OTC drugs with a significant ingestion hazard, e.g., iron containing products, acetaminophen, etc.
The Poison Prevention Packaging Act requires that, with few exceptions, all prescription drugs must be dispensed in child resistant containers (CRCs) unless either the patient or prescriber specifically requests that the drug be dispensed in a non CRC. In my personal experience it has been obvious that many pharmacists are not complying with this law. The Consumer Product Safety Commission (CPSC) is involved in enforcing this act. In at least two instances, accidental ingestions of tablets dispensed in a non CRC where a CRC was required by law occurred in young children. In Connecticut, a little girl ingested an acetaminophen and codeine combination, was treated in an emergency room and released. After an investigation by the CPSC, the pharmacist was found to not be in compliance with the law and was reprimanded by the state board of pharmacy. In Colorado, a child ingested a diphenoxylate-atropine combination under similar circumstances; required both treatment in an emergency room and hospital admission, and was discharged the day following the ingestion. In this case, an injunction was issued by the United States District Court to insure that this pharmacy would, in the future, comply with the law. Fortunately, severe injury did not occur in either case. The law provides for criminal prosecution including the possibility of both a jail sentence and a fine for each violation of the act. Failure to use CRC when one is required by law is negligence per se. 5 If an injury occurs, the possibility of a civil suit initiated on behalf of the injured party against the pharmacist involved also exists. Since a violation of the law is involved, the claim may not be covered under many pharmacy malpractice policies. For more information on CRCs see a recent article in THIS JOUBNAL by Fink. 5 Even with all these safeguards some ingestions will occur. Many of diese may be treated at home using syrup of ipecac as an emetic and thus an unnecessary emergency room visit can be avoided. Appropriately labeled one ounce containers may be dispensed OTC. It is critical that every outpatient pharmacy have syrup of ipecac available for emergency use.
In conclusion, pharmacists must be committed to reducing acute ingestion drug toxicity. The following are useful in fulfilling this obligation:
1. In selecting a drug, the acute overdose potential must be considered.
2.
In determining the amount to be prescribed or dispensed, the potential lethality of that amount must be considered. From a realistic viewpoint, it is not in the best interest of society or pharmacy to rapidly eliminate the Bachelor of Science program. From an idealistic viewpoint, all pharmacists should ultimately practice as a few of our current clinical practitioners with the Doctor of Pharmacy background do now. However, it is fallacious to assume that we can rapidly convert pharmacy practice to the type of clinical practice exemplified by these few practitioners by simply converting to a highly clinical Doctor of Pharmacy program. Each college should address itself to the following questions before deciding on the number of degree programs it can offer:
1. Is the primary educational objective of your college to prepare pharmacists for contemporary practice in community and hospital settings? If affirmative, then it would seem inappropriate to offer the clinical Doctor of Pharmacy degree as the sole professional degree of the college.
2. What type of leadership has your college provided to change phramacy practice at the city, state, and national levels? This leadership will be necessary if pharmacy practice is to change Drug Intelligence and Clinical Pharmacy VOL 11 MAR 77
